News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
PEEK brings a new quality to dental care for patients
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
